The Synairgen share price is flying! Here’s what I’d do now

The Synairgen share price rose by more than 25% in early trading on Friday. Roland Head looks at the latest news and gives his view.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The Synairgen (LSE: SNG) share price surged higher on Friday morning and is up by 28% as I write. The stock rose after positive results from the trial of a drug used to treat coronavirus patients were published in The Lancet Respiratory Medicine journal.

The trial results showed that coronavirus patients who received Synairgen’s SNG001 “inhaled formulation of interferon beta-1a” had “greater odds of improvement and recovered more quickly”.

This news isn’t a complete surprise. Synairgen’s share price rose by over 400% in one day in July when the company originally disclosed the results of this trial.

But the publication of the results in a respected, peer-reviewed journal provides an extra layer of credibility. I believe it could pave the way for the larger-scale phase-three trial that would be needed to gain commercial approval.

After the vaccine – Is it too late?

The stock market has surged this week on hopes that a Covid-19 vaccine produced by US pharma giant Pfizer could help bring the coronavirus pandemic to an end. But I think the reality is that even in a best-case scenario, rolling out the vaccine will take time and it will never be 100% effective.

In the meantime, people will continue to catch coronavirus and need treatment. The latest UK government data show that there are currently more than 14,000 Covid patients in UK hospitals. Many other countries have similar numbers.

Synairgen’s share price slumped on Monday when the vaccine news emerged. But I think it’s too soon to forget about the need for other treatments. I think there’s a good chance that SNG001 could still find a sizeable commercial market.

What happens next?

The SNG001 trial that’s being reported on today was a phase-two trial. This means it was relatively small, with just 101 patients. Drug development is a three-stage process. For SNG001 to progress towards commercial approval, a larger phase-three trial will be required.

I don’t know how long that might take to complete. But I think it’s worth looking at the broader picture. Before coronavirus took hold at the start of this year, Synairgen was trialling SNG001 for use with patients suffering from COPD, a chronic lung disease.

My understanding is that this has been put on the backburner so the firm can focus on Covid-19. But I think it’s fair to say that the work being done now could end up being useful for a broader range of respiratory conditions.

In other words, I don’t think Synairgen’s commercial potential is limited to treating Covid.

Synairgen share price is up 2,000% in 2020

Back in January, Synairgen was trading at just 6p. As I write, the stock is trading at 128p.That’s a gain of more than 2,000% in less than a year.

Am I too late to buy the shares? I think it’s hard to say. Synairgen doesn’t currently have any revenue and is loss-making. But if a large-scale trial of SNG001 is successful, I’d guess that regulatory approval could follow quite quickly.

I think Synairgen’s share price could go either way from here. Although I can see the potential for further gains, this kind of situation is beyond my personal risk tolerance. For this reason, I won’t be investing.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »